| Literature DB >> 24427413 |
Eugene K Wilson1, Kevin Deweber2, James W Berry3, John H Wilckens4.
Abstract
CONTEXT: Cutaneous infections are common in wrestlers. Although many are simply a nuisance in the everyday population, they can be problematic to wrestlers because such infections may result in disqualification from practice or competition. Prompt diagnosis and treatment are therefore important. EVIDENCE ACQUISITION: Medline and PubMed databases, the Cochrane Database of Systematic Reviews, and UpToDate were searched through 2012 with the following keywords in various combinations: skin infections, cutaneous infections, wrestlers, athletes, methicillin-resistant Staphylococcus aureus, skin and soft tissue infections, tinea corporis, tinea capitis, herpes simplex, varicella zoster, molluscum contagiosum, verruca vulgaris, warts, scabies, and pediculosis. Relevant articles found in the primary search, and selected references from those articles were reviewed for pertinent clinical information.Entities:
Keywords: cutaneous infections; herpes gladiatorum, tinea gladiatorum; skin and soft tissue infections; wrestlers
Year: 2013 PMID: 24427413 PMCID: PMC3752190 DOI: 10.1177/1941738113481179
Source DB: PubMed Journal: Sports Health ISSN: 1941-0921 Impact factor: 3.843
Guidelines for return to competition for cutaneous infections in wrestlers[64,65]
| Condition | National Collegiate Athletic Association | National Federation of State High School Associations |
|---|---|---|
| Herpes gladiatorum | No new lesions for 72 hours before the examination | No new vesicle formation and no swollen lymph nodes near the affected area |
| Resolution of all systemic symptoms in primary cases | Lesions must be well healed with well-adherent scabs | |
| All lesions must be dry and covered by a firm adherent crust; moist, active lesions cannot be covered to allow participation | If antiviral therapy used, withhold from wrestling for 5 days | |
| Treatment with appropriate systemic antiviral therapy for at least 120 hours before and at the time of competition | ||
| Bacterial skin and soft tissue infections | Completed 72 hours of antibiotic therapy | Completed 72 hours of antibiotic therapy |
| No moist or draining lesions | No moist or draining lesions, and lesion should have a well-adherent scab | |
| No new skin lesions for 48 hours before competition | Lesions should be covered with a bio-occlusive dressing until completely healed | |
| Moist or draining lesions cannot be covered for participation | ||
| Tinea gladiatorum | A minimum of 72 hours of topical antifungal therapy for tinea corporis | A minimum of 72 hours of systemic or topical antifungal therapy for tinea corporis |
| A minimum of 2 weeks of systemic antifungal therapy for tinea capitis | No specific recommendation for tinea capitis | |
| Lesions can be covered with a bio-occlusive dressing for return to competition after a period of adequate pharmacotherapy | Lesions can be covered with a bio-occlusive dressing for return to competition after a period of adequate pharmacotherapy | |
| Varicella zoster virus | Lesions must be covered with a firm adherent crust | Primary outbreaks require 10-14 days of systemic antiviral medication |
| No evidence of secondary bacterial infection | Secondary outbreaks require 5 days of systemic antiviral medication | |
| Lesions must be scabbed over with no discharge | ||
| No new lesions in preceding 48 hours | ||
| Molluscum contagiosum | Lesions must be curetted or removed | Lesions should be covered if prone to bleeding |
| Solitary or locally clustered lesions can be covered with a gas-permeable membrane and tape | ||
| Verruca vulgaris | Lesions must be “adequately covered” or curetted | Lesions should be covered if prone to bleeding |
| Facial lesions can be covered with a mask | ||
| Scabies | A negative microscopic skin prep before return to competition | |
| Pediculosis | Appropriate pharmacotherapy and completeness of response confirmed by examination |
Figure 1.Herpes gladiatorum lesions on the forehead of this wrestler appear as grouped vesicles and crusted plaques.
Select oral medications for herpes gladiatorum[8,13,19,31]
| Indication | Medication | Dosing Regimen |
|---|---|---|
| Primary infection | ||
| Adult | Acyclovir | 400 mg, PO, 3×/d, or 200 mg, PO, 5×/d for 7-10 d |
| Famciclovir | 250 mg, PO, 3×/d for 7-10 d | |
| Valacyclovir | 1000 mg, PO, 2×/d for 7-10 d | |
| ≤ 12 years old | Acyclovir | 40-80 mg/kg daily in 3 divided doses for 5-10 d (max, 1 g/d) |
| Valacyclovir | 20 mg/kg, PO, 3×/d for 5-10 d | |
| Recurrent infection | ||
| Adult | Acyclovir | 800 mg, PO, 2×/d for 5 d, or 400 mg, PO, 3×/d for 5 d |
| Famciclovir | 125 mg, PO, 2×/d for 5 d, or 1 g, PO, 2× for 1 d | |
| Valacyclovir | 1 g, PO, daily for 5 d, or 500 mg, PO, 2×/d for 3-7 d | |
| Prophylaxis | ||
| > 12 years old | Acyclovir | 400 mg, PO, 2×/d |
| Famciclovir | 250 mg, PO, 2×/d | |
| Valacyclovir | 500 mg, PO, once daily, or 1 g, PO, once daily | |
PO, orally.
Same as for primary infection, ≤ 12 years old.
Insufficient evidence to recommend use of prophylaxis in children < 12 years old.
Figure 2.Erysipelas presents as sharply demarcated red plaques. Photo courtesy of Poupou l’quourouce.
Figure 3.Cellulitis on the leg with erythema and subcutaneous edema. Photo courtesy of Colm Anderson.
Figure 4.Folliculitis in the axilla with multiple perifollicular erythematous papules and pustules.
Figure 5.A furuncle with a central follicular pustule surrounded by an inflammatory nodule.
Figure 6.Methicillin-resistant Staphylococcus aureus cutaneous abscess with spontaneous drainage. Photo courtesy of the Centers for Disease Control and Prevention/Bruno Coignard/Jeff Hageman.
Figure 7.Bullous impetigo on the arm with vesicles, bullae, and adherent brown crusts. Photo courtesy of the Centers for Disease Control and Prevention.
Select outpatient antibiotic options for bacterial skin and soft tissue infections[20,75]
| Indication | Medication | Dosage | Comments |
|---|---|---|---|
| Impetigo | |||
| Adult | Dicloxacillin | 250 mg, PO, 4× daily | |
| Cephalexin | 250 mg, PO, 4× daily | ||
| Clindamycin | 300-400 mg, PO, 3× daily | ||
| Erythromycin | 250 mg, PO, 4× daily | Some | |
| Mupirocin 2% ointment | Apply 3× daily | For areas of limited involvement | |
| Children | Dicloxacillin | 12 mg/kg/d, PO, 4 divided doses | |
| Cephalexin | 25 mg/kg/d, PO, 4 divided doses | ||
| Clindamycin | 10-20 mg/kg/d, PO, 3 divided doses | ||
| Erythromycin | 40 mg/kg/d, PO, 4 divided doses | Some | |
| Mupirocin 2% ointment | Apply 3× daily | For areas of limited involvement | |
| Skin and soft tissue infection: MSSA | |||
| Adult | Dicloxacillin | 500 mg, PO, 4× daily | |
| Cephalexin | 500 mg, PO, 4× daily | ||
| Doxycycline | 100 mg, PO, 2× daily | ||
| Clindamycin | 300-450 mg, PO, 3× daily | ||
| Children | Dicloxacillin | 25 mg/kg/d, PO, 4 divided doses | |
| Cephalexin | 25 mg/kg/d, PO, 4 divided doses | ||
| Clindamycin | 10-20 mg/kg/d, PO, 3 divided doses | ||
| Skin and soft tissue infection: MRSA | |||
| Adult | Doxycycline | 100 mg, PO, 2× daily | |
| Trimethoprim-sulfamethoxazole | 1 or 2 double-strength tablets, PO, 2× daily | ||
| Clindamycin | 300-450 mg, PO, 3× daily | Possible cross-resistance and emergence of resistance in erythromycin-resistant strains, and possible inducible MRSA resistance | |
| Linezolid | 600 mg, PO, 2× daily | ||
| Mupirocin 2% cream | Apply 3× daily | For folliculitis with an area of limited involvement | |
| Children | Trimethoprim-sulfamethoxazole | 8-12 mg/kg/d, PO, 2 divided doses | |
| Clindamycin | 10-20 mg/kg/d, PO, 3 divided doses | Possible cross-resistance and emergence of resistance in erythromycin-resistant strains, and possible inducible MRSA resistance | |
| Linezolid | 10 mg/kg/d, PO, 2 divided doses | ||
| Mupirocin 2% cream | Apply 3× daily | For folliculitis with an area of limited involvement | |
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; PO, orally.
Figure 8.Tinea capitis presents as a sharply demarcated, erythematous, scaly patch. This lesion has progressed to alopecia. Photo courtesy of the Centers for Disease Control and Prevention.
Figure 9.Tinea gladiatorum lesions on the neck of this wrestler with a typical appearance: erythematous annular plaques with central clearing and surface scale at the periphery of the lesion.
Figure 10.An abraded tinea gladiatorum lesion on the arm lacks a typical appearance.
Treatment options for tinea gladiatorum[14,41,42,53,81]
| Indication | Medication | Dosing Regimen | Comments |
|---|---|---|---|
| Tinea capitis: Diffuse/inflammatory tinea corporis treatment | |||
| Adult | Terbinafine | 250 mg, PO, daily for 2-4 wk | Potential rare hepatotoxicity, anemia, neutropenia, thrombocytopenia, agranulocytosis. LFT elevations in approximately 3%-4% treated. Possible gastrointestinal upset. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. |
| Itraconazole | 200 mg, PO, daily for 2-6 wk | Potential rare hepatotoxicity. LFT elevations in approximately 2%-4% treated. Possible gastrointestinal upset. Obtain baseline LFT and repeat every 4-6 wk during treatment. | |
| Ketoconazole | 200 mg, PO, daily for 2-4 wk | Potential severe hepatotoxicity/hepatic failure (1:10,000 treated), hemolytic anemia, neutropenia. Possible gastrointestinal upset. Avoid alcohol because of liver effects and disulfiram-type effect. Obtain baseline CBC and LFT and repeat every month during treatment. | |
| Children | Griseofulvin (micronized) | 20 mg/kg, PO, daily for 8 wk | For child >30 kg. Rare hepatotoxicity and photosensitivity. Possible leukopenia and granulocytopenia. Possible gastrointestinal upset. Obtain CBC and LFT at 6 wk of treatment. |
| Terbinafine | Weight, 10-20 kg: 62.5 mg, PO, daily for 2-4 wk | For child >2 years old. Potential rare hepatotoxicity, anemia, neutropenia, thrombocytopenia, agranulocytosis. LFT elevations in approximately 3%-4% treated. Possible gastrointestinal upset. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. | |
| Weight, 20-40 kg: 125 mg, PO, daily for 2-4 wk | |||
| Weight >40 kg: same as adult dosing | |||
| Tinea corporis: Limited area treatment | |||
| Clotrimazole cream | Applied to lesion and surrounding area twice daily | ||
| Miconazole cream | Applied to lesion and surrounding area twice daily | ||
| Terbinafine cream | Applied to lesion and surrounding area twice daily | ||
| Butenafine cream | Applied to lesion and surrounding area once daily | ||
| Prophylaxis | |||
| Adult | Fluconazole | 100 mg, PO, 1x/wk | Rare severe hepatotoxicity/hepatic failure, leukopenia, thrombocytopenia, agranulocytosis. Possible gastrointestinal upset. Avoid alcohol because of liver effects and disulfiram-type effect. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. |
CBC, complete blood count; LFT, liver function test; PO, orally.
Figure 11.Varicella zoster virus lesions initially present as erythematous papules with surface vesicles, creating a “dew drop on petal” appearance. Photo courtesy of the Centers for Disease Control and Prevention/Dr Heinz F. Eichenwald.
Figure 12.Varicella zoster virus (herpes zoster) lesions on the forehead are found in a dermatomal distribution and in various stages: vesicles, crusted papules, and crusted plaques. Photo courtesy of the Centers for Disease Control and Prevention/Dr Heinz F. Eichenwald.
Figure 13.Molluscum contagiosum presents as pearly papules measuring 1 to 10 mm with central umbilication. Photo courtesy of Evanherk (Netherlands).
Figure 14.Verruca vulgaris presents as papules with rough, hyperkeratotic, villiform surfaces; it commonly affects the hands.
Figure 15.Scabies presents as erythematous nonspecific papules that commonly appear in the interdigital web spaces. Photo courtesy of the Centers for Disease Control and Prevention.
Figure 16.Head lice appear on hair shafts and on the skin, and excoriations are present as small crusts on the skin. © DermAtlas; http://www.DermAtlas.org.